Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA3 | P07451 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1008198 | 1.00 | LMNA (0.55) | LMNACA12CA1CA2CA3 | |
| SCHEMBL1008559 | 1.00 | LMNA (0.55) | LMNACA12CA1CA2CA3 | |
| SCHEMBL1007520 | 0.98 | LMNA (0.53) | LMNACA12CA1CA2CA3 | |
| SCHEMBL1007666 | 0.98 | LMNA (0.53) | LMNACA12CA1CA2CA3 | |
| SCHEMBL1005671 | 0.98 | LMNA (0.53) | LMNACA12CA1CA2CA3 | |
| Hydrochloric Acid SCHEMBL6696404 | 0.96 | LMNA (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL30019019 | 0.85 | LMNA (0.46) | LMNACA12CA1CA2CA3 | |
| SCHEMBL23959715 | 0.83 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL14882102 | 0.83 | LMNA (0.47) | LMNACA12CA1CA2CA3 | |
| SCHEMBL10514836 | 0.83 | SLC6A3 (0.55) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105488-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | CHLORION PHARMA, INC. (CA) | 2011-05-05 | — | — | US | claimed |
| EP-2268616-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | Chlorion Pharma, Inc. (CA) | 2011-01-05 | — | — | EP | claimed |
| WO-2009114950-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | CHLORION PHARMA, INC. (CA) | 2009-09-24 | — | — | WO | claimed |
| US-20230183177-A1 | ENANTIOSELECTIVE CHEMO-ENZYMATIC SYNTHESIS OF OPTICALLY ACTIVE AMINO AMIDE COMPOUNDS | PHARMAZELL GMBH (DE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183177-A1 | ENANTIOSELECTIVE CHEMO-ENZYMATIC SYNTHESIS OF OPTICALLY ACTIVE AMINO AMIDE COMPOUNDS | PHARMAZELL GMBH (DE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183177-A1 | ENANTIOSELECTIVE CHEMO-ENZYMATIC SYNTHESIS OF OPTICALLY ACTIVE AMINO AMIDE COMPOUNDS | PHARMAZELL GMBH (DE) | 2023-06-15 | — | — | US | disclosed |
| US-20230159452-A1 | REGIOSELECTIVE OXIDATION OF HETEROCYCLIC ALPHA-AMINO AMIDES | PHARMAZELL GMBH (DE) | 2023-05-25 | — | — | US | disclosed |
| US-20230159452-A1 | REGIOSELECTIVE OXIDATION OF HETEROCYCLIC ALPHA-AMINO AMIDES | PHARMAZELL GMBH (DE) | 2023-05-25 | — | — | US | disclosed |
| CN-115956127-A | Enantioselective chemoenzymatic synthesis of optically active aminoamide compounds | 细胞制药有限公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-115916746-A | Regioselective oxidation of heterocyclic alpha-aminoamides | 细胞制药有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4139468-A1 | ENANTIOSELECTIVE CHEMO-ENZYMATIC SYNTHESIS OF OPTICALLY ACTIVE AMINO AMIDE COMPOUNDS | Pharmazell GmbH (DE) | 2023-03-01 | — | — | EP | disclosed |
| US-7563912-B2 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of Levetiracetam and analogues | UCB PHARMA, S.A. (BE) | 2009-07-21 | — | — | US | disclosed |
| EP-1810676-B1 | Levetiracetam formulations and methods for their manufacture | TEVA PHARMA (IL) | 2008-11-12 | — | — | EP | disclosed |
| EP-1419144-B1 | OXOPYRROLIDINE COMPOUNDS, PREPARATION OF SAID COMPOUNDS AND THEIR USE IN THE MANUFACTURING OF LEVETIRACETAM AND ANALOGUES | UCB PHARMA SA (BE) | 2008-10-08 | — | — | EP | disclosed |
| US-20070142647-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | ATES CELAL | 2007-06-21 | — | — | US | disclosed |
| US-20060258734-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of Levetiracetam and analogues | UCB PHARMA, S.A. (BE) | 2006-11-16 | — | — | US | disclosed |
| US-7122682-B2 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | UCB, S.A. (BE) | 2006-10-17 | — | — | US | disclosed |
| US-20040204476-A1 | Oxopyrrolidine compounds, preparations of said compounds and their use in the manufacturing of levetiracetam and analogues | UCB PHARMA, S.A. (BE) | 2004-10-14 | — | — | US | disclosed |
| EP-1419144-A2 | OXOPYRROLIDINE COMPOUNDS, PREPARATION OF SAID COMPOUNDS AND THEIR USE IN THE MANUFACTURING OF LEVETIRACETAM AND ANALOGUES | UCB, S.A. (BE) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003014080-A2 | OXOPYRROLIDINE COMPOUNDS, PREPARATION OF SAID COMPOUNDS AND THEIR USE IN THE MANUFACTURING OF LEVETIRACETAM AND ANALOGUES | UCB, S.A. (BE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183177-A1 | ENANTIOSELECTIVE CHEMO-ENZYMATIC SYNTHESIS OF OPTICALLY ACTIVE AMINO AMIDE COMPOUNDS | COASY, NAAA, HNMT | LMNA 3882/4885CA12 1144/4885CA1 360/4885 |
| US-20040204476-A1 | Oxopyrrolidine compounds, preparations of said compounds and their use in the manufacturing of levetiracetam and analogues | CYP2C19, CYP2C9, TPMT | LMNA 3589/4885CA12 2116/4885CA1 1011/4885 |
| US-20110105488-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | PAM, PNN, NOD1 | LMNA 2396/4885CA12 4726/4885CA1 4343/4885 |
| US-20060258734-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of Levetiracetam and analogues | TPMT, CYP2C9, OTC | LMNA 2489/4885CA12 2370/4885CA1 1525/4885 |
| US-20230159452-A1 | REGIOSELECTIVE OXIDATION OF HETEROCYCLIC ALPHA-AMINO AMIDES | CBR1, ABAT, CYP2E1 | LMNA 3211/4885CA12 1361/4885CA1 332/4885 |
| US-20070142647-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | CYP2D6, OTC, CYP2B6 | LMNA 2327/4885CA12 2417/4885CA1 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.